Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 1 **February 2001**

CONTENTS

Editorial 1

COMMENTARY

The Rate and Extent of Oral Bioavailability versus the Rate and Extent of Oral Absorption: Clarification and Recommendation of Terminology 3
Win L. Chiou

PHARMACOKINETICS/PHARMACODYNAMICS

Peripheral Link Model as an Alternative for Pharmacokinetic–Pharmacodynamic Modeling of Drugs Having a Very Short Elimination Half-Life 7
Julie Laurin, François Donati, Fahima Nekka, and France Varin

A Whole-Body Physiologically Based Pharmacokinetic Model Incorporating Dispersion Concepts: Short and Long Time Characteristics 27
Ruth E. Oliver, Alan F. Jones, and Malcolm Rowland

Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition 57
Wojciech Krzyzanski and William J. Jusko

Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults 79
David M. Reith, Wayne D. Hooper, John Parke, and Bruce Charles

PHARMACOMETRICS

An Identifiability Analysis of a Parent–Metabolite Pharmacokinetic Model for Ivabradine 93
Neil D. Evans, Keith R. Godfrey, Michael J. Chapman, Michael J. Chappell, Leon Aarons, and Stephen B. Duffull

ANNOUNCEMENTS 107

Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 2 **April 2001**

CONTENTS

PHARMACOKINETICS/PHARMACODYNAMICS

Time-Dependent Oral Absorption Models 109
Kazutaka Higaki, Shinji Yamashita, and Gordon L. Amidon

In vivo Cerebral Pharmacokinetics and Pharmacodynamics of Diazepam and Midazolam after Short Intravenous Infusion Administration in Sheep 129
Richard N. Upton, Guy L. Ludbrook, Cliff Grant, and Allison Martinez

On Sample Size Calculation in Bioequivalence Trials 155
Shein-Chung Chow and Hansheng Wang

PHARMACOMETRICS

Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check 171
Yoshitaka Yano, Stuart L. Beal, and Lewis B. Sheiner

Is Mixed Effects Modeling or Naïve Pooled Data Analysis Preferred for the Interpretation of Single Sample per Subject Toxicokinetic Data? 193
Jeremy P. Hing, Steven G. Woolfrey, Dennis Greenslade, and Peter M. C. Wright

Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 3 **June 2001**

CONTENTS

PHARMACOKINETICS/PHARMACODYNAMICS

A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide 211
Alwin D. R. Huitema, Ron A. A. Mathôt, Matthijs Tibben, Sjoerd Rodenhuis, and Jos H. Beijnen

PHARMACOMETRICS

Assessment of Actual Significance Levels for Covariate Effects in NONMEM 231
Ulrika Wählby, E. Niclas Jonsson, and Mats O. Karlsson

Efficient Screening of Covariates in Population Models Using Wald's Approximation to the Likelihood Ratio Test 253
Kenneth G. Kowalski and Matthew M. Hutmacher

In Vivo–In Vitro Correlation (IVIVC) Modeling Incorporating a Convolution Step 277
T. O'Hara, S. Hayes, J. Davis, J. Devane, T. Smart, and A. Dunne

Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children 299
France Mentré, Catherine Dubruc, and Jean-Paul Thénot

Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 4 August 2001

CONTENTS

Population Pharmacokinetic–Pharmacodynamic Modeling of Filgrastim (r-metHuG-CSF) in Healthy Volunteers 321
B. Wang, T. M. Ludden, E. N. Cheung, G. G. Schwab, and L. K. Roskos

PHARMACOMETRICS

Selecting Reliable Pharmacokinetic Data for Explanatory Analyses of Clinical Trials in the Presence of Possible Noncompliance 343
J. Lu, J.-M. Gries, D. Verotta, and L. B. Sheiner

Impact of Pharmacokinetic–Pharmacodynamic Model Linearization on the Accuracy of Population Information Matrix and Optimal Design 363
Y. Merlé and M. Tod

The Need For Mixed-Effects Modeling with Population Dichotomous Data 389
I. Yano, S. L. Beal, and L. B. Sheiner

ERRATUM

Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults 413
D. M. Reith, W. D. Hooper, J. Parke, and B. Charles

Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 5 **October 2001**

CONTENTS

PHARMACOKINETICS/PHARMACODYNAMICS

Quantitative Evaluation of Capacity-Limited Hepatobiliary Transport Based on Hepatocellular Diffusion Model by MULTI(FEM) 415
Mitsuo Higashimori, Kiyoshi Yamaoka, Sumiaki Fujitani, and Terumichi Nakagawa

A Stochastic Model Describes the Heterogeneous Pharmacokinetics of Cyclosporin 445
Laurent Claret, Athanassios Iliadis, and Panos Macheras

PHARMACOMETRICS

Analysis of Toxicokinetic Data using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data 465
J. P. Hing, S. G. Woolfrey, D. Greenslade, and P. M. C. Wright

Ways to Fit a Pharmacokinetic Model with Some Data Below the Quantification Limit 481
Stuart L. Beal

Announcements 505

Journal of Pharmacokinetics and Pharmacodynamics

Vol. 28, No. 6 **December 2001**

CONTENTS

General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition 507
Donald E. Mager and William J. Jusko

Quantitative Relationship between Myocardial Concentration of Tacrolimus and QT Prolongation in Guinea Pigs: Pharmacokinetic/Pharmacodynamic Model Incorporating a Site of Adverse Effect 533
Tsuyoshi Minematsu, Hisakazu Ohtani, Yasuhiko Yamada, Yasufumi Sawada, Hitoshi Sato, and Tatsuji Iga

Population Pharmacokinetics and Pharmacodynamics of Sotalol in Pediatric Patients with Supraventricular or Ventricular Tachyarrhythmia 555
Jun Shi, Thomas M. Ludden, Armen Melikian, Marc R. Gastonguay, and Peter H. Hinderling

PHARMACOMETRICS

Information Tools for Exploratory Data Analysis in Population Pharmacokinetics 577
Olivier Petricoul, Laurent Claret, Dominique Barbolosi, Athanassios Iliadis, and Christian Puozzo

ANNOUNCEMENT: Pharmacokinetic–Pharmacodynamic Modeling 601

ANNOUNCEMENT: Principles of Pharmacokinetics and Toxicokinetics 603

Author Index to Volume 28 605

Subject Index to Volume 28 607